Grifols, S.A. (GRFS) vs Novo Nordisk A/S (NVO)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| GRFS | NVO | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| Size band | MID | LARGE |
| Listing | Nasdaq GS | NYSE |
| Country | Spain | Denmark |
| Theme | rare-disease | glp-1-and-obesity |
| Price and returns | ||
| Last close | $7.92 | $39.13 |
| Return · 1 week | +3.66% | +1.85% |
| Return · 1 month | +6.88% | +1.08% |
| Return · 3 months | −1.00% | −23.21% |
| Return · year to date | −14.29% | −22.57% |
| Return · 1 year | −15.57% | −23.30% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −20.00% | −39.01% |
| 52-week high | $9.90 | $64.16 |
| 52-week low | $6.96 | $35.12 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $5.39B | $172.64B |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $3.03M | $405.29M |
| Employees | 25,258 | 66,700 |
| Valuation | ||
| Price to earnings · trailing | 9.69× | 9.14× |
| Price to earnings · forward | 5.17× | 11.33× |
| Price to sales | 0.68× | 0.52× |
| Price to book | 1.63× | 5.19× |
| Enterprise value to EBITDA | 13.05× | 1.54× |
| Enterprise value to revenue | 2.89× | 0.81× |
| PEG ratio | 0.19 | 4.35 |
| Earnings per share · trailing | 0.77 | 4.25 |
| Profitability | ||
| Gross margin | 36.98% | 80.65% |
| Operating margin | 15.90% | 42.54% |
| Profit margin | 6.09% | 35.35% |
| Return on equity | 6.93% | 59.82% |
| Return on assets | 4.23% | 18.73% |
| Growth | ||
| Revenue growth | −0.90% | +2.10% |
| Earnings growth | +32.90% | −20.60% |
| Balance sheet and payout | ||
| Debt / equity (%) | 117.24 | 63.33 |
| Current ratio | 2.37 | 0.87 |
| Dividend yield | 1.41% | 4.63% |
| Payout ratio | 37.97% | 43.10% |
| Trend and volatility | ||
| RSI · 14 | 64.63 | 46.28 |
| ADX · 14 | 12.03 | 20.53 |
| 50-day average | $7.58 | $41.77 |
| 200-day average | $8.02 | $44.60 |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 2.58% | 1.91% |
The full GRFS analysis
Everything this table leaves out for Grifols, S.A.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the GRFS argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full GRFS analysisThe full NVO analysis
Everything this table leaves out for Novo Nordisk A/S: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the NVO argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full NVO analysis